Sleep and Breathing in the General Population - Chemical Stimuli
Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
Central sleep apnea (CSA) is a common condition and its treatment remains elusive. The focus
of this proposal is to identify the role of the physiologic path involving cortical arousals
in CSA by decreasing arousal frequency using the pharmacological agent zolpidem. The goal is
to identify the acute effects of administering zolpidem on sleep and respiratory outcomes,
and subsequently, its effect on the severity of CSA and propensity to develop CSA. This study
will shed light on the mechanisms underlying CSA that involve cortical arousals and will
guide future therapeutic interventions for CSA.